Arvinas, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARVN Nasdaq 2834 www.arvinas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arvinas, Inc.

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - Jun 13th, 2025 5:00 am
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - Jun 6th, 2025 5:00 am
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting - Jun 5th, 2025 6:28 am
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - May 31st, 2025 6:00 am
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? - May 30th, 2025 7:55 am
Arvinas to Present at Jefferies Global Healthcare Conference - May 30th, 2025 5:00 am
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm - May 29th, 2025 8:29 am
Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - May 4th, 2025 6:36 am
Here are 1 Main Capital Partners’ Views on Arvinas (ARVN) - May 2nd, 2025 7:19 am
Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... - May 2nd, 2025 1:03 am
Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates - May 1st, 2025 6:15 am
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 1st, 2025 5:00 am
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Apr 29th, 2025 8:01 am
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - Apr 28th, 2025 5:00 am
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting - Apr 28th, 2025 4:45 am
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 23rd, 2025 8:44 am
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting - Apr 21st, 2025 5:00 am
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple - Apr 9th, 2025 7:43 am
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN) - Apr 9th, 2025 7:35 am
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study - Apr 4th, 2025 1:38 pm